Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 638 citing articles:

Immunology of COVID-19: Current State of the Science
Nicolas Vabret, Graham J. Britton, Conor Gruber, et al.
Immunity (2020) Vol. 52, Iss. 6, pp. 910-941
Open Access | Times Cited: 1668
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1124
Gene therapy clinical trials worldwide to 2012 – an update
Samantha L. Ginn, Ian E. Alexander, Michael Edelstein, et al.
The Journal of Gene Medicine (2013) Vol. 15, Iss. 2, pp. 65-77
Closed Access | Times Cited: 1094
Therapeutic cancer vaccines
Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3401-3412
Open Access | Times Cited: 1048
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 4, pp. 209-222
Open Access | Times Cited: 887
Carcinogenic human papillomavirus infection
Mark Schiffman, John Doorbar, Nicolas Wentzensen, et al.
Nature Reviews Disease Primers (2016) Vol. 2, Iss. 1
Closed Access | Times Cited: 848
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg, Ramon Arens, Ferry Ossendorp, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 4, pp. 219-233
Closed Access | Times Cited: 649
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth, Kathrin U. Jansen
npj Vaccines (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 613
Cancer vaccines: the next immunotherapy frontier
Matthew J. Lin, Judit Svensson‐Arvelund, Gabrielle S. Lubitz, et al.
Nature Cancer (2022) Vol. 3, Iss. 8, pp. 911-926
Closed Access | Times Cited: 594
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Asmita Pal, Rita Kundu
Frontiers in Microbiology (2020) Vol. 10
Open Access | Times Cited: 458
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
Erminia Massarelli, William William, Faye M. Johnson, et al.
JAMA Oncology (2018) Vol. 5, Iss. 1, pp. 67-67
Open Access | Times Cited: 417
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
R. Wang, Wei Pan, Jin Lei, et al.
Cancer Letters (2019) Vol. 471, pp. 88-102
Open Access | Times Cited: 384
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Margaret A. Liu
Vaccines (2019) Vol. 7, Iss. 2, pp. 37-37
Open Access | Times Cited: 378
Cervical Cancer Screening: Past, Present, and Future
Sarah L. Bedell, Lena Sophia Goldstein, Amelia Goldstein, et al.
Sexual Medicine Reviews (2019) Vol. 8, Iss. 1, pp. 28-37
Open Access | Times Cited: 347
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes, Gaëlle Vandermeulen, Véronique Préat
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 336
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad, Christine C. Roberts, Kristin T Mills, et al.
The Lancet Infectious Diseases (2019) Vol. 19, Iss. 9, pp. 1013-1022
Open Access | Times Cited: 291
Cervical Cancer Immunotherapy: Facts and Hopes
Louise Ferrall, Ken Y. Lin, Richard B.S. Roden, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 18, pp. 4953-4973
Open Access | Times Cited: 267
Cervical cancer therapies: Current challenges and future perspectives
Carly A. Burmeister, Saif F. Khan, Georgia Schäfer, et al.
Tumour Virus Research (2022) Vol. 13, pp. 200238-200238
Open Access | Times Cited: 266
Induction of resident memory T cells enhances the efficacy of cancer vaccine
Mevyn Nizard, Hélène Roussel, Mariana O. Diniz, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 265
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Pablo Tebas, ShuPing Yang, Jean Boyer, et al.
EClinicalMedicine (2020) Vol. 31, pp. 100689-100689
Open Access | Times Cited: 262
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
Filippo Veglia, Vladimir A. Tyurin, Dariush Mohammadyani, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 248
Clinical potential of electroporation for gene therapy and DNA vaccine delivery
Laure Lambricht, Alessandra Lopes, Špela Kos, et al.
Expert Opinion on Drug Delivery (2015) Vol. 13, Iss. 2, pp. 295-310
Closed Access | Times Cited: 216
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine
Pablo Tebas, Christine C. Roberts, Kar Muthumani, et al.
New England Journal of Medicine (2017) Vol. 385, Iss. 12, pp. e35-e35
Open Access | Times Cited: 214
Controlling timing and location in vaccines
Darrell J. Irvine, Aereas Aung, Murillo Silva
Advanced Drug Delivery Reviews (2020) Vol. 158, pp. 91-115
Open Access | Times Cited: 213
The dawn of vaccines for cancer prevention
Olivera J. Finn
Nature reviews. Immunology (2017) Vol. 18, Iss. 3, pp. 183-194
Closed Access | Times Cited: 212
Page 1 - Next Page

Scroll to top